drugset / Trial / NCT06297772
Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR
RandomizedParallel-groupOpen-labelTreatment
Summary
A multicenter, randomized, controlled clinical study comparing the efficacy and safety of allogeneic hematopoietic stem cell transplantation with decitabine-Fludarabine- busulfan (Dec-FB4) and Fludarabine-busulfan (FB4) as pretreatment regimens for the treatment of acute myeloid leukemia in adults with MR gene abnormalities
Timeline
- Start
- 2024-06-01
- Primary completion
- 2026-03-01
- Completion
- 2028-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 20 mg/m2 | — |
| Background | Busulfan | Small molecule | 3.2 mg/kg | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |